Subhankar Mukhopadhyay
Overview
Explore the profile of Subhankar Mukhopadhyay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2000
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Onyishi C, Jeon Y, Fejer G, Mukhopadhyay S, Gordon S, May R
Eur J Immunol
. 2024 Mar;
54(6):e2350771.
PMID: 38494423
Vomocytosis, also known as nonlytic exocytosis, is a process whereby fully phagocytosed microbes are expelled from phagocytes without discernible damage to either the phagocyte or microbe. Although this phenomenon was...
2.
Mukhopadhyay S, To K, Liu Y, Bai C, Leung S
Biomater Sci
. 2023 Nov;
12(1):151-163.
PMID: 37937608
Chronic skin wounds are often associated with multidrug-resistant bacteria, impeding the healing process. Bacteriophage (phage) therapy has been revitalized as a promising strategy to counter the growing concerns of antibiotic...
3.
McLaren P, Porreca I, Iaconis G, Mok H, Mukhopadhyay S, Karakoc E, et al.
Nature
. 2023 Sep;
621(7979):E42.
PMID: 37670157
No abstract available.
4.
Onyishi C, Desanti G, Wilkinson A, Lara-Reyna S, Frickel E, Fejer G, et al.
Nat Commun
. 2023 Aug;
14(1):4895.
PMID: 37580395
The opportunistic fungal pathogen Cryptococcus neoformans causes lethal infections in immunocompromised patients. Macrophages are central to the host response to cryptococci; however, it is unclear how C. neoformans is recognised...
5.
Mukhopadhyay S, Zhang P, To K, Liu Y, Bai C, Leung S
Int J Antimicrob Agents
. 2023 Aug;
62(5):106951.
PMID: 37574030
Bacteriophage (phage) therapy, exploiting phages which are the natural enemies of bacteria, has been re-introduced to treat multidrug-resistant (MDR) bacterial infections. However, some intrinsic drawbacks of phages are overshadowing their...
6.
McLaren P, Porreca I, Iaconis G, Mok H, Mukhopadhyay S, Karakoc E, et al.
Nature
. 2023 Aug;
620(7976):1025-1030.
PMID: 37532928
HIV-1 remains a global health crisis, highlighting the need to identify new targets for therapies. Here, given the disproportionate HIV-1 burden and marked human genome diversity in Africa, we assessed...
7.
Randzavola L, Mortimer P, Garside E, Dufficy E, Schejtman A, Roumelioti G, et al.
Elife
. 2022 Nov;
11.
PMID: 36421765
EROS (essential for reactive oxygen species) protein is indispensable for expression of gp91, the catalytic core of the phagocyte NADPH oxidase. EROS deficiency in humans is a novel cause of...
8.
Mukhopadhyay S, Veroniaina H, Chimombe T, Han L, Zhenghong W, Xiaole Q
RSC Adv
. 2022 May;
9(61):35566-35578.
PMID: 35528069
Protean mesoporous silica nanoparticles (MSNs) are propitious candidates over decades for nanoscale drug delivery systems due to their unique characteristics, including (but not limited to) changeable pore size, mesoporosity, high...
9.
Douthwaite H, Arteagabeitia A, Mukhopadhyay S
Bio Protoc
. 2022 Apr;
12(6):e4361.
PMID: 35434184
As a model to interrogate human macrophage biology, macrophages differentiated from human induced pluripotent stem cells (hiPSCs) transcend other existing models by circumventing the variability seen in human monocyte-derived macrophages,...
10.
Masetti M, Carriero R, Portale F, Marelli G, Morina N, Pandini M, et al.
J Exp Med
. 2021 Dec;
219(2).
PMID: 34919143
Tumor-associated macrophages (TAMs) are correlated with the progression of prostatic adenocarcinoma (PCa). The mechanistic basis of this correlation and therapeutic strategies to target TAMs in PCa remain poorly defined. Here,...